Location:Home > Xiangya News > News

Professor Shen Liangfang’s team published the latest clinical study result of nasopharyngeal carcinoma treatment in The Lancet


The team of Professor Shen Liangfang, Director of the Department of Oncology of Xiangya Hospital, Central South University recently co-conducted a large-scale, prospective, phase 3 clinical study led by the team of Professor Ma Jun from Sun Yat-sen University Cancer Center. This study pioneers a model in which metronomic capecitabine is deployed as the adjuvant therapy after the chemoradiotherapy for nasopharyngeal carcinoma. The study result has been published in The Lancet (IF 60.393) as an original article entitled Metronomic Capecitabine as Adjuvant Therapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A multicentre, Open-label, Parallel-group, Randomised, Controlled, Phase 3 Trial. Attending physician Zhou Qin from the team of Professor Shen is one of the first authors.


The comprehensive treatment with definitive concurrent chemoradiotherapy has been adopted for patients suffering from locoregionally advanced nasopharyngeal carcinoma in which distant metastasis is the leading cause of treatment failure. The previous clinical studies on additional adjuvant chemotherapy failed to find effective survival benefits. NCT02958111, a randomized, double-blind, controlled clinical study, led by Professor Ma gives low-dose oral metronomic capecitabine as the adjuvant chemotherapy for one year, showing that metronomic capecitabine can significantly improve failure-free survival at three years (85.3% vs 75.7%, P=0.0023). This is the first large-scale, randomized, controlled clinical study in the world obviously illustrating that adjuvant chemotherapy can benefit patients with locoregionally advanced nasopharyngeal carcinoma. This finding will provide the best treatment plan for higher survival of patients with nasopharyngeal carcinoma.

Professor Shen’s team has been focusing on the prevention and treatment of head and neck tumors such as nasopharyngeal carcinoma, a typical disease in China. Despite the development of radiotherapy and comprehensive treatment, patients with nasopharyngeal carcinoma still face high risk of death. Improving the survival of patients with nasopharyngeal carcinoma and their life quality has been a constant research question. At present, Professor Shen’s team has led multiple clinical studies, and established long-term cooperation with teams of Professor Ma and Professor Chen Mingyuan. Joint efforts have been made to clinical studies of locoregionally advanced nasopharyngeal carcinoma, and recurrence and metastasis from nasopharyngeal carcinoma. On July 23, 2020, Associate Professor He Yuxiang from Professor Shen’s team published an original article with the title of Efficacy and Safety of Locoregional Radiotherapy With Chemotherapy vs Chemotherapy Alone in De Novo Metastatic Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial in JAMA Oncology (IF 24.799) as one of the first authors. The team has published more than 60 SCI papers in internationally-renowned journals such as Cancer Research (IF 9.725), Theranostics (IF 8.576), Oncogene (IF 7.970), Cell Death and Disease (IF 6.303), which has formed academic advantages and impact in the field.

Link to the original text:

Xiangya Hospital Central South University
All Rights Reserved.